EN DE
Watch Monsenso AS for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Monsenso AS (MONSO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Monsenso AS stock DKK 0.19, price DKK 0.22, that is 14.4% below the price, quality 23 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DK · ISIN DK0061277977

MA Monsenso AS logo Thin data Nov 10, 2026

Monsenso AS

MONSO · CO
Expensive, weak quality

Our calculation puts a fair price 14% below what the stock costs today.

Low debt
Revenue last quarter 36% below a year ago.
Fair value kr 0.1884 · Overvalued
Quality 23/100
Weak Growth (revenue 5y −0.3 %/yr in DKK)
Loss-making · -95.7% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 10/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Monsenso AS for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 8.85 kr 0.1000 Fair Value kr 0.1884 Apr 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.1000 – kr 8.85 · fair‑value band kr 0.1413 – kr 0.2355 · the kr 0.2200 price screens above the kr 0.1884 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Monsenso AS in your weekly email

Every Wednesday you see whether Monsenso AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Monsenso A/S develops and sells digital health solution for the treatment of depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, and addiction and substance abuse in Denmark.

Show moreShow less

The company offers Monsenso app for individuals that collects patient-reported and sensor data providing insights into symptoms, adherence, and outcomes.

It also provides Monsenso solution, a software as a medical device for mental health professionals application that has data collection, direct messaging, visualization and feedback, psychoeducation and cognitive behavioral therapy, medication reminders, task reminders, consultation prepration, and platform integration that allows monitor patients remotely.

In addition, the company offers Monsenso app for carers. Monsenso A/S was incorporated in 2013 and is based in Frederiksberg, Denmark.

Stock analysis

Monsenso AS (MONSO) currently trades at kr 0.2200, while our estimate is kr 0.1884, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.1413 (bear) to kr 0.2355 (bull), the price of kr 0.2200 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Monsenso AS reported revenue of 8.9M DKK in FY2025 versus 7.1M DKK in FY2021, a compound +5.7%/yr. Reported net income was −7.2M DKK in FY2025.

Key figures

Market cap 22.1M DKK (≈ $3.3M) Micro · P/S ratio 3.56 · EPS (TTM) kr −0.0900 · Net margin −95.7% · Return on equity −79.3% · Return on assets (EBIT) −41.0% (5-year average) · Operating margin −101% · Revenue (TTM) 7.1M DKK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 120% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at −14%, MONSO screens cheaper than that median.

Fair Value

Bear kr 0.1413 Fair Value kr 0.1884 Bull kr 0.2355
Price kr 0.2200 · Downside -14.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 19
How much profit the company makes from its sales and capital
Quality Growth 18
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 28
How calm the share price moves, does not count
Price momentum 50
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 45
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−20.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Start year 2020 (pandemic). Over 10 years: +21.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.8% (2020) → −87.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MONSO screens overvalued: fair value 14% below the price. Compare with Veeva Systems Inc →

Compare Monsenso AS with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 141 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −14.4% · Above median
Profitability
Return on assets −55.3% · Bottom 25%
Net margin (12 months) −95.7% · Bottom 25%
Operating margin (12 months) −100.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −35.6% · Bottom 25%
Balance sheet
Debt / equity 0.24× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 3.17× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 3.13× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)14 · sector 13
FUTURE (revenue growth)0 · sector 45
PAST (return on equity)0 · sector 0
HEALTH (low debt)88 · sector 98
DIVIDEND (yield)0 · sector 46

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.42 $36.16 +12% vs MONSO
Veeva Systems Inc VEEV $305.55 $337.04 +10% vs MONSO
HealthEquity, Inc HQY $103.54 $112.32 +8% vs MONSO
Waystar Holding WAY $29.30 $29.10 −1% vs MONSO
Tempus AI, Inc TEM $80.54 $52.58 −35% vs MONSO
HeartFlow, Inc HTFL $55.80 $34.82 −38% vs MONSO
Hinge Health, Inc HNGE $123.23 $51.25 −58% vs MONSO
Pro Medicus Limited PME A$207.31 A$85.12 −59% vs MONSO
BrightSpring Health Services, Inc BTSG $72.49 $25.72 −65% vs MONSO
XtalPi Holdings 2228 HK$6.37 HK$1.53 −76% vs MONSO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Monsenso AS: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Monsenso AS Fair Value". https://www.fairvalue-calculator.com/stock/MONSO

Frequently asked questions

Is Monsenso AS (MONSO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.1884 versus a price of kr 0.2200, about 14% lower (overvalued).
What is the fair value of MONSO?
Our estimate for Monsenso AS is kr 0.1884 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.2200.
What is the quality score of MONSO?
Monsenso AS has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Monsenso AS (MONSO)?
Our calculated price target is the estimate of kr 0.1884 (as of Nov 10, 2026). Cautious scenario kr 0.1413, optimistic scenario kr 0.2355. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Monsenso AS stock forecast for 2026?
Our estimate puts fair value at kr 0.1884, about 14% lower versus a price of kr 0.2200 (overvalued). Cautious scenario kr 0.1413, optimistic scenario kr 0.2355. The calculation is refreshed regularly with new filings.
What is the revenue of Monsenso AS (MONSO)?
Monsenso AS reported trailing-twelve-month revenue of about 7.1M DKK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Monsenso AS (MONSO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Monsenso AS it is kr 0.1884 per share (as of Nov 10, 2026), against a price of kr 0.2200.
Is Monsenso AS stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MONSO trades above its calculated fair value: price kr 0.2200, fair value kr 0.1884, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MONSO?
No. The price is what the market pays today (kr 0.2200); the fair value is what the company's own numbers justify (kr 0.1884). For Monsenso AS the two are kr 0.0316 per share apart. That gap is exactly why we show both numbers side by side.
How much is Monsenso AS worth?
The market values Monsenso AS at about 22.1M DKK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.2200; our models calculate a fair value of kr 0.1884 per share.
What do the bullish and bearish scenarios say about MONSO?
Our models span a range for Monsenso AS: cautious scenario kr 0.1413, base kr 0.1884, optimistic kr 0.2355 per share (as of Nov 10, 2026, price kr 0.2200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Monsenso AS (MONSO)?
Balance-sheet figures for Monsenso AS (as of Nov 10, 2026): return on equity −79.3%, debt of 0.24 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is MONSO from its 52-week high?
Monsenso AS trades at kr 0.2200, about 55% below its 52-week high of kr 0.4840 and 120% above the low of kr 0.1000 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1884 is for.
Which stocks are comparable to Monsenso AS?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Monsenso AS stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.2200, calculated fair value kr 0.1884 (−14%), Quality Score 23/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Monsenso AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Monsenso AS (MONSO)?
The closing price on Nov 10, 2026 was kr 0.2200. Our estimate is kr 0.1884, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Monsenso AS right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Monsenso AS

How large is the market capitalisation of Monsenso AS (MONSO)?
The market capitalisation of Monsenso AS is 22.1M DKK (≈ $3.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Monsenso AS (MONSO)?
The price-to-sales ratio of Monsenso AS is 3.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Monsenso AS (MONSO)?
Earnings per share at Monsenso AS are kr −0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Monsenso AS (MONSO)?
The net margin of Monsenso AS is −95.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Monsenso AS (MONSO)?
The return on equity (ROE) of Monsenso AS is −79.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Monsenso AS (MONSO)?
On an EBIT basis the return on assets of Monsenso AS is −41.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Monsenso AS (MONSO)?
The operating margin of Monsenso AS is −101% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Monsenso AS (MONSO)?
Revenue at Monsenso AS is growing −35.6% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Monsenso AS (MONSO) generate?
The free cash flow of Monsenso AS is −1.5M DKK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Monsenso AS (MONSO) carry?
The net debt of Monsenso AS is 1.8M DKK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Monsenso AS in the live analysis

One click puts Monsenso AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.